The role of biomarkers in the management of patients with rheumatoid arthritis.
In recent years, patient outcomes have improved dramatically with the availability of effective treatments for the management of rheumatoid arthritis (RA). RA, however, is a heterogeneous disease with variable disease progression and treatment response. Whereas some patients respond to a single disease-modifying antirheumatic drug, others require more intensive treatment strategies. Assessing disease severity at diagnosis and monitoring disease activity on an individual level would be a more accurate way of tailoring therapy, ensuring optimal treatment for those at greatest risk of disease progression, long-term disability, and joint damage without unnecessary overtreatment. Assessment of disease activity and severity is currently based on a combination of clinical and laboratory parameters that aid treatment decisions. Use of biomarkers may provide a more accurate means of objectively assessing the disease. This article reviews the role of biomarkers in the management of RA.
Nam
Jackie
J
Academic Unit of Musculoskeletal Diseases, 2nd Floor Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, United Kingdom.
Villeneuve
Edith
E
Emery
Paul
P
D001172:Arthritis, Rheumatoid / Q000378:metabolism / Q000503:physiopathology / Q000534:rehabilitation; D015415:Biomarkers / Q000378:metabolism*; D018450:Disease Progression; D006304:Health Status; D006801:Humans; D008991:Monitoring, Physiologic; D057285:Precision Medicine; D012720:Severity of Illness Index; D016896:Treatment Outcome
D015415:Biomarkers